country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P991294

Copy Link Print Information

MGTA-117 Antibody

MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy.

For research use only. We do not sell to patients.

Purity: 99.50%

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

MGTA-117 Antibody Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- Description
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Species Reactivity

Human

IC₅₀ & Target

c-Kit/CD117

In Vitro

MGTA-117 (0.1-1.0 mg/kg) rapidly and selectively binds and depletes CD117+ cells (human hematopoietic stem cells and AML tumor cells) with IC₅₀ s of <10 pM^[1].
MGTA-117 effectively depletes more than 95% of human hematopoietic stem and progenitor cells (HSPCs) in AML murine models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MGTA-117 (0.1 mg/kg, i.v., once for 21 days) has a short half-life with a t_1/2 of 91 h and selectively depletes ≥95% HSPCs in humanized NSG (hNSG) mice^[1,2].
MGTA-117(3 & 10 mg/kg, once or 3 mg/kg, QODx2) significantly increases survival of a 2.4-2.7-fold in Kasumi-1 xenograft hNSG mice model^[2].
MGTA-117 (3 & 10 mg/kg, once) significantly decreases peripheral tumor burden, delays tumor growth, and increases survival in AML PDX 1 (2-3.3 fold) and AML PDX 2 (1.3-1.8 fold) xenograft hNSG mice models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gene ID

3815 [NCBI]

Accession

P10721

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

Application

ELISA, FACS, Functional assay

Chemical Information

Appearance Liquid
Color colorless
SMILES

[MGTA-117 Antibody]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (260 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Artz A S, et al. TIP: A phase I/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB) [J]. 2022.

[2]. Lanieri L, et al. A single dose of a novel anti-human CD117-amanitin antibody drug conjugate (ADC) engineered for a short half-life provides dual conditioning and anti-leukemic activity and extends survival compared to standard of care in multiple preclinical models of acute myeloid leukemia (AML)[J]. Blood, 2020, 136: 47-48.

[3]. Kitawi R, et al. Advances in HIV Gene Therapy. Int J Mol Sci. 2024 Feb 28; 25(5):2771. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote